tbuckley/cabot-search huggingface dataset:
Studies on the Antimitotic Activity of Leurocristine (Vincristine)
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of combined sequential treatment of sipuleucel-T followed by enzalutamide in metastatic chemotherapy-naive castration resistant prostate cancer: Results of single center of large urology group.
Authors: Vladimir Mouraviev, Christopher Michael Pieczonka, David Albala
Journal: Journal of Clinical Oncology (2014)

e16099 Background: The results of the IMPACT trial demonstrated that immunotherapy as monotherapy is not sufficient enough to hinder or stop progression of mCRPC especially with high baseline PSA level. Therefore, the timing and sequencing of combination therapy is becoming of outmost importance for the treatment of these patients. As a result, our hypothesis has been to layer on enzalutamide very quickly after the completion of sipuleucel-T. Methods: We collected the data of 84 patients with chemo-naïve mCRPC treated with sipuleucel-T at our practice from September 2011 to January 2014. Prior to the initiation of treatment the baseline status was recorded in all patients. We then selected and analyzed outcomes of 19 patients who received sequential enzalutamide treatment off label after completion of sipuleucel-T with the average timing in 3.2±2.1 months. Results: The median time of enzalutamide therapy was 5.4 months (range: 1-13). In our cohort of 19 patients: 1 case showed radiographic full regression of metastatic lesions in bone, lung and lymph nodes. Another case showed radiographic full regression of bony metastatic lesions. 2 other cases – showed a partial regression radiographically of bony metastatic disease. 13 cases showed stable disease according to RECIST-criteria. The remaining 2 patients were deceased due to progression of mCRPC. The patients with full and partial response were in the lowest quartile of our cohort as defined as a PSA ≤ 3.87 ng/ml. On the contrary, all cases of progression and death were documented in highest (last) quartile as defined by a PSA level more than 84 ng/ml. Conclusions: Our experience demonstrates a promising effect using sequential sipuleucel-T immunotherapy followed by enzalutamide for mCRPC. To our knowledge this will be the first case of complete radiographic regression of lung, bone, and extensive lymph node disease.
THE RAPID DIAGNOSIS OF RABIES.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiac transplantation in an 8-month-old female infant with subendocardial fibroelastosis
Authors: D. A. Cooley
Journal: JAMA (1986)

On Nov 1, 1984, an orthotopic cardiac transplantation was performed in an 8-month-old female infant with subendocardial fibroelastosis. Because of the advanced state of cardiac failure, the operation was done despite a positive tissue crossmatch for antitoxic donor-specific antibodies. Immunosuppression consisted of high doses of cyclosporine (up to 550 mg/m<sup>2</sup>or 30 mg/kg) and steroids. Hypertension and tremor of the extremities, which were attributed to cyclosporine, occurred during the first week but resolved after seven days. No signs of nephrotoxic effects have been noted; however, a severe episode of allograft rejection was detected by endomyocardial biopsy on the seventh postoperative day, and a moderate rejection episode was noted on the 22nd postoperative day. Histologic improvement was seen after treatment with conventional steroid pulses. The patient was discharged on Nov 29, 1984. Complications consisted of four episodes of otitis media caused by<i>Staphylococcus aureus</i>and one rejection episode that was treated on an outpatient basis with an intravenous methylprednisolone sodium succinate pulse. Our experience emphasizes both the feasibility and importance of performing endomyocardial biopsies in infant recipients. Through biopsy, episodes of rejection can be discovered when clinical signs are not yet apparent. Eighteen months after transplantation, the child was developing and growing normally. (<i>JAMA</i>1986;256:1326-1329)
CHLOROPHYL AND HEMOGLOBIN
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Substitutes for Whole Milk
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentaire de travail de Z. Jin et al., pp. 314
Journal: Endoscopy (2008)

See also: Endoscopic ultrasonography-guided interstitial implantation of iodine 125-seeds combined with chemotherapy in the treatment of unresectable pancreatic carcinoma: a prospective pilot studyEndoscopy 2008; 40(04): 314-320DOI: 10.1055/s-2007-995476
* Rectal mucosal biomarkers of colorectal cancer risk are increased in morbidly obese patients but not significantly different six months after sleeve gastrectomy
Authors: P. Kant, S. Dexter, M. A. Hull
Journal: Gut (2011)

<h3>Introduction</h3> We have previously shown that putative mucosal biomarkers of colorectal cancer (CRC) risk (rectal epithelial cell mitosis frequency and crypt size) are significantly higher in morbidly obese (body mass index (BMI) &gt;40 kg/m<sup>2</sup>) patients than normal weight controls. These biomarkers were further increased up to 3 years after Roux-en-Y gastric bypass (RYGB), despite significant weight loss. We tested whether CRC risk biomarkers were similarly affected by sleeve gastrectomy (SG), a form of bariatric surgery not associated with malabsorption secondary to intestinal bypass. <h3>Methods</h3> Serum and rectal mucosa were obtained from 18 morbidly obese patients (mean BMI 64.1 kg/m<sup>2</sup>) before and 6 months after SG, as well as from 18 non-obese (BMI 24.7 kg/m<sup>2</sup>) patients undergoing anal canal surgery. Mucosal biomarkers were measured after whole crypt micro-dissection. Mucosal pro-inflammatory gene expression was measured by real-time PCR. Serum C-reactive protein (CRP), tumour necrosis factor (TNF)-α and interleukin (IL)-6 levels were measured by immunoassay. <h3>Results</h3> Before SG, morbidly obese patients had a higher epithelial cell mitosis frequency (mean 4.8 cells per crypt) compared with non-obese controls (3.3 cells per crypt, p&lt;0.05), with a luminal shift in the distribution of mitotic cells. Morbidly obese patients had larger rectal crypts (mean area 0.039 vs 0.033 mm<sup>2</sup>; p&lt;0.01) than non-obese individuals. SG was associated with a mean excess weight loss (EWL) of 38.6% at 6 months (similar to the mean EWL after RYGB). Following SG, serum CRP decreased from a median level of 17.5 mg/l to 9.9 mg/l (p&lt;0.001), but there was no significant change in serum IL-6 or TNFα levels. Unlike after RYGB, there was no significant change in epithelial cell mitosis frequency or crypt size 6 months after SG. The only mucosal pro-inflammatory gene transcript to significantly increase 6 months after SG (1.5-fold, 95% CI 1.1 to 2.1, p&lt; 0.05) was macrophage migration inhibitory factor (MIF). <h3>Conclusion</h3> We have confirmed that mucosal CRC risk biomarkers are elevated in morbidly obese patients compared with non-obese individuals. Significant SG-induced weight loss was not associated with lower CRC risk biomarker values. Unlike RYGB, SG was not associated with a significant increase in epithelial cell mitosis frequency or crypt size 6 months after surgery. However, SG was associated with increased mucosal expression of the pro-tumourigenic cytokine MIF, consistent with our previous observations in RYGB patients. Post-surgical mucosal and inflammatory biomarkers vary in morbidly obese patients depending on the type of bariatric surgery undertaken. Prospective studies of colorectal neoplastic risk in obese patients after bariatric surgery are warranted.
Abstract 2226: International Cancer Genome Consortium (ICGC)
Authors: Jennifer L. Jennings, Thomas J. Hudson
Journal: Cancer Research (2010)

Abstract The International Cancer Genome Consortium (ICGC) is one of most ambitious biomedical research efforts since the Human Genome Project. The ICGC is coordinating an international-scale research effort to obtain a comprehensive description of genomic, transcriptomic and epigenomic changes in the major forms of cancer. This information will lead to better ways of diagnosing, treating and preventing cancer. The ICGC was launched in April 2008, with the announcement of the proposed strategies and policies to the international scientific community to enable funding agencies and research groups to plan their participation within the ICGC. As of December 2009, the ICGC has received commitments from funding organizations in Asia, Australia, Europe and North America for the following cancer genome projects: breast cancer, Her2+ (France); breast cancer, multiple subtypes (United Kingdom); chronic lymphocytic leukemia (Spain); gastric adenocarcinoma (China), hepatocellular carcinoma, alcohol and associated etiologies (France); pediatric brain cancers - medulloblastoma and pilocytic astrocytoma (Germany); hepatocellular carcinoma, viral etiologies (Japan); oral cavity cancer (India), and pancreatic adenocarcinoma (Australia and Canada). Furthermore, the latest call for proposals published in the Health Theme of the European Union's 7th Research Framework Programme includes a research topic to support European participation in the ICGC. The ICGC projects will complement a large US-based pilot project called The Cancer Genome Atlas, which oversees projects related to glioblastoma multiforme, squamous carcinoma and serous adenocarcinoma. Over time, additional nations and organizations Each project is expected to involve specimens from approximately 500 patients. Over the next ten years, the ICGC expects to produce comprehensive catalogues of the full range of genetic mutations involved in 50 types of cancer, with key factors being the ability to detect all mutated cancer genes, data at the level of individual DNA bases, application of common standards for pathology and technology and comparison data from matched, non-tumour tissue. The ICGC's informed consent and ethical oversight policies state that cancer patients enrolled in an ICGC-related study should be informed that their participation is voluntary, that their clinical care will not be affected by their participation and that data obtained from analyses using their samples will be made available to the international research community. ICGC projects will use common standards of data collection and analysis. The ICGC will make its data rapidly and freely available to the global research community. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2226.
Malpractice Suits
Authors: Harlan B. Moss
Journal: JAMA (1978)

<h3>To the Editor.—</h3> After reading the letter of Mr Alan Y. Medvin (240:346, 1978), "I feel compelled to respond." Mr Medvin contends that many malpractice actions are settled before trial because they generally involve the clearest cases of malpractice. I strongly doubt this statement. There are many nuisance cases that are settled out of court because insurance carriers find that it is less expensive to do it that way. The merits of these cases are ignored.
Exertional heatstroke in novice runners
Authors: P. G. Hanson
Journal: JAMA (1979)

Heatstroke occurred in four apparently normal but inexperienced runners who were involved in road races of 10, 16, 32, and 42 km. Each of the runners attempted to increase his running pace by approximately 1 min/km during the last 5 km of the race. Symptoms of heatstroke occurred within five to ten minutes of the onset of increased effort. In three cases, environmental conditions (temperatures, 24 to 26 °C) were contributory. Specific guidelines and instructions are needed for inexperienced runners who enter distance road races. (<i>JAMA</i>242:154-157, 1979)
Insulin Sensitivity and Glucose Tolerance Are Altered by Maintenance on a Ketogenic Diet
Authors: Kimberly P. Kinzig, Mary Ann Honors, Sara L. Hargrave
Journal: Endocrine Reviews (2010)

kisspeptin in the control of hypothalamic DA and pituitary PRL secretion in adult rats.Intracerebroventricular kisspeptin-10 (Kp-10) elicited PRL release in a dose-dependent manner in estradiol (E2)-treated ovariectomized (OVX) rats (OVXϩE2), whereas no effect was found in oil-treated ovariectomized rats (OVX).Kp-10 increased PRL release in males and proestrous but not diestrous females.Associated with the increase in PRL release, intracerebroventricular Kp-10 reduced Fos-related antigen expression in tyrosine hydroxylase-immunoreactive (ir) neurons of arcuate and periventricular nuclei in OVXϩE2 rats, with no effect in OVX rats.Kp-10 also decreased 3,4-dihydroxyphenylacetic acid concentration and 3,4-dihydroxyphenylacetic acid-DA ratio in the median eminence but not striatum in OVXϩE2 rats.Double-label immunofluorescence combined with confocal microscopy revealed kisspeptin-ir fibers in close apposition to and in contact with tyrosine hydroxylase-ir perikarya in the arcuate.In addition, Kp-10 was not found to alter PRL release from anterior pituitary cell cultures regardless of E2 treatment.We provide herein evidence that kisspeptin regulates PRL release through inhibition of hypothalamic dopaminergic neurons, and that this mechanism is E2 dependent in females.These findings suggest a new role for central kisspeptin with possible implications for reproductive physiology.
THE SCHOOL CHILD'S BREAKFAST
Journal: JAMA (2009)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE MECCA PILGRIMAGE.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Trickle-Down Theory of Cleaner Air
Authors: Lance Frazer
Journal: Environmental Health Perspectives (2000)

The 1990 Clean Air Act Amendments prompted an increased urgency to find new ways to treat airstreams containing volatile organic compounds, which affect the nitrogen photolytic cycle and help produce ground-level ozone, hazardous air pollutants, and odorous air emissions such as hydrogen sulfide. Scientists at the New Jersey company Envirogen have adapted traditional biofiltration technology to perform airborne waste stream cleanup. Preliminary research on pollutants such as phenol, methylene chloride, benzene, and toluene indicates that Envirogen's biotrickling filter may remove an average of about 94% of total hazardous air pollutants. Scientists are working to identify microbes that will clean up more stubborn pollutants.
Literary Honors.
Journal: JAMA (1884)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA (2019)

Resuscitation Strategies for Patients With Septic Shock 654Shock is characterized by increased serum lactate and tissue hypoperfusion.Hernández and colleagues randomized 424 patients with septic shock and found that a resuscitation strategy targeting normalization of capillary refi ll time, compared with a strategy targeting serum lactate levels, did not reduce all-cause 28-day mortality.In an Editorial, Angus suggests that these resuscitation strategies are straightforward, inexpensive, and complementary.